ClinicalTrials.gg
TerminatedNCT02202746Updated Jun 23, 2020Results posted

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

A Phase 2 interventional study of Lucitanib in Breast Cancer, Metastatic Breast Cancer and MBC, sponsored by Clovis Oncology, Inc.. Terminated at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Clovis Oncology, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to end monotherapy development of the compound in breast cancer.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF non-aberrant) metastatic breast cancer.

Read the detailed description

Lucitanib is a selective, orally available tyrosine kinase inhibitor targeting FGFR1-3, VEGFR1-3, and PDGFRα and β, with activity in relevant cell lines and animal models.

The first in human trial of lucitanib demonstrated that daily dosing with lucitanib can provide durable clinical responses in patients with FGFR1- or 11q (FGF3, FGF4, Cyclin D1, or FGF19)-amplified breast cancer. RECIST partial responses (PRs) were also observed in patients not known to have FGF abnormalities.

Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in breast cancer patients with and without alterations of the FGF pathway.

02

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer
  • MBC
  • HER2 Positive
  • HER2
  • Estrogen Receptor Positive
  • ER
  • Triple Negative

Browse trials for

Keywords

  • Breast cancer
  • Metastatic breast cancer
  • MBC
  • HER2 positive
  • HER2+
  • Estrogen receptor positive
  • ER+
  • Triple negative
  • FGFR1
  • 11q
  • FGF aberrant
  • Biomarker negative
  • FGF non-aberrant
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 178 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Clovis Oncology, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed breast cancer to approved standard available treatment
  • Prior treatment with standard therapy in the metastatic setting
  • Availability of tumor tissue sufficient for confirmatory testing of FGFR1 and 11q amplification status
  • Demonstrated progression of disease by radiological or clinical assessment ( according to Version 1.1 is NOT required for enrollment)
  • Estimated >6 months

Exclusion criteria

Exclusion Criteria:

  • Current or recent treatment with biologic anticancer therapies
  • Ongoing AEs from prior anticancer therapies
  • Active central nervous system (CNS)
  • or uncontrolled hypertension or cardiac disease
  • Females who are pregnant or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Cohort A: Lucitanib (CO-3810) 10 mg daily

    10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.

    Drug: Lucitanib

  • Experimental
    Cohort B: Lucitanib (CO-3810) 15 mg daily

    15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.

    Drug: Lucitanib

  • Experimental
    Cohort C: Lucitanib (CO-3810) 10 mg daily

    10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.

    Drug: Lucitanib

Interventions

  • Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)

    Also known as: CO-3810

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator

    The primary efficacy endpoint of PFS was calculated as 1+ the number of days from the date of first dose of study drug to disease progression or death due to any cause, whichever occurs first. Patients without a documented event of progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment), or the date of randomization if no tumor assessments were performed. Progression events were determined by the investigator. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

    Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months

Secondary outcomes

  1. Objective Response Rate (ORR) by RECIST v1.1

    ORR is the percentage of patients with a best response of CR or PR according to RECIST v1.1. The best response is recorded from the start of the treatment (Day 1) until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.

    Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months

  2. Duration of Response (DR) by RECIST v1.1

    DR for complete response (CR) and partial response (PR) was measured from the date that any of these best confirmed responses was first recorded until the first date that PD was objectively documented. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.

    Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months

  3. Disease Control Rate (DCR) by RECIST v1.1

    The DCR is defined as the percentage of patients with a best response rate of CR, PR, or SD for at least 12 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started.

    Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months

  4. Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Cmax

    The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Cmax = maximum concentration following administration of lucitanib.

    Time frame: Study Day -7 to Study Day 1, or approximately 8 days

  5. Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Tmax

    The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Tmax = time to maximum concentration following administration of lucitanib

    Time frame: Study Day -7 to Study Day 1, or approximately 8 days

  6. Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUClast

    The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUClast = area under the plasma concentration time curve from time 0 to the last quantifiable time point (24 hour)

    Time frame: Study Day -7 to Study Day 1, or approximately 8 days

  7. Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUCinf

    The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUCinf = area under the plasma concentration time curve from 0 to infinity

    Time frame: Study Day -7 to Study Day 1, or approximately 8 days

  8. Relative Bioavailability Analysis for Tablet vs Capsule - Cmax, AUClast, AUCinf

    Relative bioavailability of lucitanib was evaluated by comparison of (log-transformed) AUClast, Cmax and AUCinf of the tablet formulation to the capsule formulation using an analysis of variance (ANOVA) model with treatment as a fixed effect. The geometric means, ratio of the geometric means and 90% confidence intervals (CI) on the ratio of Tablet to Capsule (T:R) were presented for AUClast, Cmax and AUCinf. The CIs on the ratio of untransformed PK parameters were derived through reverse transformation of the 90% CI of the difference in the log scale to the 90% CI of the ratio in the original scale.

    Time frame: Study Day -7 to Study Day 1, or approximately 8 days

  9. Overall Survival

    Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.

    Time frame: Cycle 1 Day 1 to date of death, assessed up to 29 months

  10. Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score

    FACT-B is used for assessment of health-related quality of life (QoL) in participants with breast cancer. It consists of 37 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (10 items) ranging from 0 to 40; high subscale score represents a better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. FACT-B Total Score is derived from adding the five subscale scores. Total possible score ranges from 0 to 148. High scale score represents a better QoL.

    Time frame: From Cycle 1 Day 1 until end of treatment, assessed up to 29 months

07

Results

Posted Jun 23, 2020

Participant flow

178 patients were recruited from 32 sites in the United States.

Participant flow — Overall Study
MilestoneLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Started10969
Completed10969
Not completed00

Outcome measures

PrimaryProgression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator

The primary efficacy endpoint of PFS was calculated as 1+ the number of days from the date of first dose of study drug to disease progression or death due to any cause, whichever occurs first. Patients without a documented event of progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment), or the date of randomization if no tumor assessments were performed. Progression events were determined by the investigator. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Time frame:
From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Reported as:
Median · Days
Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator
DaysLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator93 (78 to 140)77 (50 to 86)
SecondaryObjective Response Rate (ORR) by RECIST v1.1

ORR is the percentage of patients with a best response of CR or PR according to RECIST v1.1. The best response is recorded from the start of the treatment (Day 1) until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.

Time frame:
From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by RECIST v1.1
percentage of participantsLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDAll Patients
Objective Response Rate (ORR) by RECIST v1.14.71.53.5
SecondaryDuration of Response (DR) by RECIST v1.1

DR for complete response (CR) and partial response (PR) was measured from the date that any of these best confirmed responses was first recorded until the first date that PD was objectively documented. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.

Time frame:
From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Reported as:
Median · Days
Duration of Response (DR) by RECIST v1.1
DaysLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Duration of Response (DR) by RECIST v1.1175 (44 to 209)336 (336 to 336)
SecondaryDisease Control Rate (DCR) by RECIST v1.1

The DCR is defined as the percentage of patients with a best response rate of CR, PR, or SD for at least 12 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started.

Time frame:
From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Reported as:
Number · percentage of patients
Disease Control Rate (DCR) by RECIST v1.1
percentage of patientsLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDAll Patients
Disease Control Rate (DCR) by RECIST v1.148.134.342.8
SecondaryComparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Cmax

The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Cmax = maximum concentration following administration of lucitanib.

Time frame:
Study Day -7 to Study Day 1, or approximately 8 days
Reported as:
Mean · ng/mL
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Cmax
ng/mLLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Tablet292 ± 156278 ± 99.8
Capsule265 ± 137285 ± 121
SecondaryComparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Tmax

The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Tmax = time to maximum concentration following administration of lucitanib

Time frame:
Study Day -7 to Study Day 1, or approximately 8 days
Reported as:
Median · Hours
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Tmax
HoursLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Tablet1.0 (0.5 to 4.0)1.0 (0.5 to 2.5)
Capsule1.5 (1.0 to 4.0)1.0 (1.0 to 2.5)
SecondaryComparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUClast

The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUClast = area under the plasma concentration time curve from time 0 to the last quantifiable time point (24 hour)

Time frame:
Study Day -7 to Study Day 1, or approximately 8 days
Reported as:
Mean · h*ng/mL
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUClast
h*ng/mLLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Tablet2550 ± 11502840 ± 1230
Capsule2650 ± 13802420 ± 613
SecondaryComparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUCinf

The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUCinf = area under the plasma concentration time curve from 0 to infinity

Time frame:
Study Day -7 to Study Day 1, or approximately 8 days
Reported as:
Mean · h*ng/mL
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUCinf
h*ng/mLLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Tablet4780 ± 21405720 ± 3760
Capsule5680 ± 27304620 ± 1620
SecondaryRelative Bioavailability Analysis for Tablet vs Capsule - Cmax, AUClast, AUCinf

Relative bioavailability of lucitanib was evaluated by comparison of (log-transformed) AUClast, Cmax and AUCinf of the tablet formulation to the capsule formulation using an analysis of variance (ANOVA) model with treatment as a fixed effect. The geometric means, ratio of the geometric means and 90% confidence intervals (CI) on the ratio of Tablet to Capsule (T:R) were presented for AUClast, Cmax and AUCinf. The CIs on the ratio of untransformed PK parameters were derived through reverse transformation of the 90% CI of the difference in the log scale to the 90% CI of the ratio in the original scale.

Time frame:
Study Day -7 to Study Day 1, or approximately 8 days
Reported as:
Number · Percentage (tablet/capsule)
Relative Bioavailability Analysis for Tablet vs Capsule - Cmax, AUClast, AUCinf
Percentage (tablet/capsule)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Cmax Geometric Mean Ratio111.73 (70.35 to 177.45)100.56 (64.59 to 156.55)
AUClast Geometric Mean Ratio97.58 (60.61 to 157.09)112.2 (78.73 to 159.89)
AUCinf Geometric Mean Ratio82.9 (51.75 to 132.81)114.23 (70.09 to 186.15)
SecondaryOverall Survival

Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.

Time frame:
Cycle 1 Day 1 to date of death, assessed up to 29 months
Reported as:
Median · Months
Overall Survival
MonthsLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDAll Patients
Overall Survival15.0 (10.7 to 17.3)7.7 (6.1 to 10.3)10.7 (8.5 to 13.7)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score

FACT-B is used for assessment of health-related quality of life (QoL) in participants with breast cancer. It consists of 37 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (10 items) ranging from 0 to 40; high subscale score represents a better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. FACT-B Total Score is derived from adding the five subscale scores. Total possible score ranges from 0 to 148. High scale score represents a better QoL.

Time frame:
From Cycle 1 Day 1 until end of treatment, assessed up to 29 months
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score
units on a scaleLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDAll Patients
Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score-2.422 ± 15.5134-7.586 ± 17.0709-4.307 ± 16.2248

Adverse events

Collected over Adverse events were reported from the time of first dose of lucitanib through 28 days after last dose protocol-specified treatment administration, up to approximately 30 months. In addition, study procedure-related AEs that occur after signing of the informed consent form and before administration of lucitanib were also collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lucitanib (CO-3810) 10 mg QD5/109 (4.6%)31/109 (28.4%)107/109 (98.2%)
Lucitanib (CO-3810) 15 mg QD7/69 (10.1%)22/69 (31.9%)69/69 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1095/69
HypoxiaRespiratory, thoracic and mediastinal disorders1/1093/69
NauseaGastrointestinal disorders1/1092/69
VomitingGastrointestinal disorders0/1092/69
HypertensionVascular disorders2/1092/69
HyponatraemiaMetabolism and nutrition disorders3/1091/69
DysphagiaGastrointestinal disorders2/1090/69
PneumoniaInfections and infestations2/1091/69
HeadacheNervous system disorders2/1090/69
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1091/69
Most frequent other events
Showing 10 of 59
Most frequent other events
EventLucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QD
HypertensionVascular disorders85/10950/69
FatigueGeneral disorders55/10937/69
HypothyroidismEndocrine disorders41/10934/69
NauseaGastrointestinal disorders53/10933/69
HeadacheNervous system disorders42/10924/69
VomitingGastrointestinal disorders35/10924/69
Decreased appetiteMetabolism and nutrition disorders36/10921/69
ProteinuriaRenal and urinary disorders22/10922/69
DiarrhoeaGastrointestinal disorders33/10919/69
DyspnoeaRespiratory, thoracic and mediastinal disorders22/10914/69

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
Median57.0 (27 to 82)53.0 (27 to 80)55.0 (27 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
Female10967176
Male022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
White8761148
Asian538
Black10111
Not provided437
Unknown/Not assessed213
Other101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
Hispanic or Latino8614
Not Hispanic or Latino9761158
Not Provided426
Number of Prior Anticancer Therapies
Number of Prior Anticancer Therapies(Therapies)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
Median6.0 (1 to 18)6.0 (1 to 16)6.0 (1 to 18)
Fibroblast Growth Factor (FGF) Status
Fibroblast Growth Factor (FGF) Status(Participants)Lucitanib (CO-3810) 10 mg QDLucitanib (CO-3810) 15 mg QDTotal
11q342559
FGFR1502878
FGFR1 & 11q181028
Negative7613
08

Study locations

33 sites
  • Arizona Oncology Associates
    Sedona, Arizona 86336, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Saint Jude Heritage Medical Center
    Fullerton, California 92835, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Cancer Care Associates Medical Group, Inc.
    Redondo Beach, California 90277, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Central Coast Medical Oncology Group
    Santa Maria, California 93454, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • University of Miami
    Deerfield Beach, Florida 33442, United States
  • Memorial West Cancer Center
    Hollywood, Florida 33021, United States
  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Horizon Oncology Center
    Lafayette, Indiana 47905, United States
  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Cooper University Hospital
    Voorhees, New Jersey 08043, United States
  • Sciode Medical Associates, PLLC
    Bronx, New York 10469, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Breast Center
    New York, New York 10065, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Austin Central
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • US Oncology
    Houston, Texas 77024, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Liao M, Zhou J, Wride K, Lepley D, Cameron T, Sale M, Xiao J. Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. Eur J Drug Metab Pharmacokinet. 2022 Sep;47(5):711-723. doi: 10.1007/s13318-022-00773-w. Epub 2022 Jul 18. PubMed 35844029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Jan 2017, 28 months.

Results were first posted in Jun 2020, 3 years 5 months after primary completion. A results delay was requested in Aug 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2014
First posted
Jul 29, 2014
StartActual
Sep 9, 2014
Primary completionActual
Jan 17, 2017
CompletionActual
Jan 18, 2017
Results delay requested
Aug 5, 2019
Results first posted
Jun 23, 2020
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02202746
Lead sponsor
Clovis Oncology, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2014
Start date
Sep 9, 2014
Primary completion
Jan 17, 2017
Completion
Jan 18, 2017
Results posted
Jun 23, 2020
Last update
Jun 23, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E-3810

Start the discussion